Found: 15
Select item for more details and to access through your institution.
Issue Information.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 285, doi. 10.1002/jcph.1659
- Publication type:
- Article
2021 JCP Reviewer Thank You List.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 440, doi. 10.1002/jcph.2028
- Publication type:
- Article
Response to Letter to the Editor by Dr Robinson.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 385, doi. 10.1002/jcph.1972
- By:
- Publication type:
- Article
Preventing a New Tuskegee: Food and Drug Administration Oversight of Overseas Research Must Match That in the United States.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 434, doi. 10.1002/jcph.1976
- By:
- Publication type:
- Article
Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 291, doi. 10.1002/jcph.2017
- By:
- Publication type:
- Article
Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 409, doi. 10.1002/jcph.1991
- By:
- Publication type:
- Article
Pediatric Drug Development Studies for Familial Hypercholesterolemia Submitted to the US Food and Drug Administration Between 2007 and 2020.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 397, doi. 10.1002/jcph.1973
- By:
- Publication type:
- Article
Conflation of Tuskegee Study With FDA Fiduciary Responsibilities Sensationally Ignores International Law.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Pharmacodynamic Modeling of CDK4/6 Inhibition-Related Biomarkers and the Characterization of the Relationship Between Biomarker Response and Progression-Free Survival in Patients With Advanced Breast Cancer.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 376, doi. 10.1002/jcph.1971
- By:
- Publication type:
- Article
Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 422, doi. 10.1002/jcph.1974
- By:
- Publication type:
- Article
Evaluation of Individualized Cefepime Dosing Strategy Using Population Pharmacokinetics.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 359, doi. 10.1002/jcph.1967
- By:
- Publication type:
- Article
Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 320, doi. 10.1002/jcph.1988
- By:
- Publication type:
- Article
Use of Propensity Scoring and Its Application to Real-World Data: Advantages, Disadvantages, and Methodological Objectives Explained to Researchers Without Using Mathematical Equations.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 304, doi. 10.1002/jcph.1989
- By:
- Publication type:
- Article
Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 3, p. 366, doi. 10.1002/jcph.1970
- By:
- Publication type:
- Article